Background: Optimization of the antibiotics for patients with infections due to MDR Pseudomonas aeruginosa (MDR-PA) often requires consideration of alternate dose and infusion times that can be influenced by renal function.
Introduction
Ceftolozane/tazobactam is a combination cephalosporin/b-lactamase inhibitor approved for use in combination with metronidazole for complicated intra-abdominal infections and as monotherapy against complicated urinary tract infections. 1 It is also in Phase 3 clinical development for treatment of nosocomial pneumonia. 2, 3 Surveillance studies show that ceftolozane/tazobactam is highly active in vitro against MDR Pseudomonas aeruginosa (MDR-PA). [4] [5] [6] The ceftolozane/tazobactam susceptibility breakpoint for P. aeruginosa is an MIC ,4 mg/L and 2011-12 surveillance data from European hospitals suggest that 84.5% of isolates were susceptible. 6 Notably, ceftolozane/tazobactam had an MIC 50 of 4 mg/L for MDR-PA strains compared with 1 mg/L for all P. aeruginosa strains from the aforementioned surveillance study. 6 As expected, antibiotic selection and dose optimization is extremely challenging for critically ill patients with infections when they have MDR-PA isolates with ceftolozane/tazobactam MICs 4 mg/L as they tend to be resistant to most commercially available antibiotics. 4, 5 Given the limited treatment options for patients with MDR-PA infections, this investigation sought to identify pharmacodynamic (PD) optimized ceftolozane/tazobactam dosing schemes against infections due to P. aeruginosa strains with ceftolozane/tazobactam MICs between 4 and 32 mg/L using a previously published pharmacokinetic (PK) model. We simulated the profiles of standard, extended and continuous infusion ceftolozane/tazobactam dosing regimens to identify dosing schemes that optimized the V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
probability of target attainment (PTA) profiles for patients with different levels of estimated renal function.
Patients and methods

Population PK model
A previously published ceftolozane/tazobactam population PK model was used to generate distributions of concentration-time profiles (n " 5000/ simulation) through Monte Carlo simulation (ADAPT 5; Biomedical Simulations Resource, Los Angeles, CA, USA). 7 The PK profile of tazobactam was not simulated as it does not affect the in vitro microbiological activity of ceftolozane against P. aeruginosa. 8 The structural PK model was parameterized as a two-compartment model with zero-order infusion and firstorder inter-compartmental transfer and elimination (Table S1 , available as Supplementary data at JAC Online). For this model, ceftolozane clearance was a function of creatinine clearance (CL CR ) and volume of the central compartment was a function of weight. Between-subject variability and between-occasion variability were modelled using an exponential model. Residual unexplained variability was modelled using an additive and proportional error model.
Monte Carlo simulation
The mean parameter vector and covariance matrix from the population PK model were embedded in Subroutine PRIOR of the ADAPT 5. The population simulation used the 'without process noise' option. The weight simulations were set to the original population distribution with a mean (range) of 79.6 (43-173) kg. One hundred and twenty-eight permutations of dose, infusion time and renal function scenarios (5000 subjects/each) were simulated. Log-normal distributions of CL CR were simulated using the mean value (33% covariance) for each renal function scenario with truncation at the specified range. Ceftolozane/tazobactam dosing regimens simulated were: (i) 3 g (2/1 g) every 8 h % 3 doses; (ii) 1.5 g (1/0.5g) every 8 h% 3 doses; (iii) 750 mg (500/250 mg) every 8 h % 3 doses; and (iv) 375 mg (250/ 125 mg) every 8 h % 3 doses. These doses were simulated based on eight different rates of infusion: 1 (current standard), 2, 3, 4, 5, 6 and 7 h as extended infusions, as well as continuous infusion over 24 h. The designated PK/PD index for ceftolozane/tazobactam against P. aeruginosa was 40% free ceftolozane concentration time above the MIC (fT .MIC ). 9 The percentage fT .MIC was computed using a value of 0.79 for the unbound fraction of ceftolozane. 1 The fraction of simulated subjects who achieved 90%, ,90%-60% and ,60% PTA for each regimen at 40% fT .MIC between 16 and 24 h (after the third dose) was calculated for MDR-PA infections with ceftolozane/tazobactam MICs between 4 and 32 mg/L for each CL CR distribution. Rather than taking an expectation of PTA using an MIC distribution from an antimicrobial susceptibility surveillance programme and calculating the cumulative fraction of response, we chose to look at PTA at each MIC value in log2 dilutions between 4 and 32 mg/L.
Results
Results of the simulation analyses are shown in Figure 1 with actual percentage PTA tabulated in 
Discussion
Modelling and simulation is a powerful tool to gain insights into optimal antimicrobial dose selection for complex scenarios with MDR pathogens that are less feasible to study clinically. 10 This investigation successfully identified PK/PD optimized ceftolozane/tazobactam dosing schemes for the treatment of P. aeruginosa infections for 512 alternate scenarios that encompassed MICs between 4 and 32 mg/L and four renal function distributions (Figure 1 ) at daily doses and dosing intervals documented for safety. In certain scenarios, it was necessary to extend the infusion duration to optimize the ceftolozane/tazobactam PK/PD profile, a methodology that enhances the activity of b-lactams against infections due to less susceptible P. aeruginosa isolates.
The simulation studies identified potentially lower doses as acceptable (90% PTA) than currently recommended for patients for treatment of P. aeruginosa infections with ceftolozane/tazobactam MICs 4 or 8 mg/L. Even among patients with augmented renal clearance, ceftolozane/tazobactam 750 mg (500/250 mg) infused over 4-5 h was associated with a 90% probability of achieving 40% fT .MIC for P. aeruginosa infections with ceftolozane/tazobactam MICs 8 mg/L. Despite this finding, we cannot encourage using lesser than approved dosing regimens empirically based on the simulation results since the MIC for the invading P. aeruginosa isolate is largely unknown at the time of therapy initiation. Given the importance of early, appropriate therapy and high morbidity and mortality associated with infections due to P. aeruginosa, 11, 12 we strongly advocate using empirical ceftolozane/tazobactam regimens for patients in a given renal function category that ensures adequate PTA for P. aeruginosa infections with ceftolozane/tazobactam MICs up to 32 mg/L.
The PK/PD target evaluated in this investigation of 40% fT .MIC is a breakpoint associated with a 2 log 10 P. aeruginosa organism load reduction in a neutropenic mouse thigh infection model. 9 While achievement of this PK/PD target is reassuring and supported by the efficacy data from the complicated urinary tract infection and complicated intra-abdominal infection studies, findings from a hollow-fibre infection model study of a clinical P. aeruginosa isolate (ceftolozane/tazobactam MIC of 4 mg/L) suggest that higher ceftolozane/tazobactam doses (2/1 g) are needed to prevent ontherapy resistance emergence in seriously ill patients with infections associated with P. aeruginosa. 13 This investigation also examined free concentrations in the plasma and the reported PTA profiles likely underestimate those observed in the epithelial lining fluid of the lung.
14 For the aforementioned reasons, a lower than approved ceftolozane/tazobactam dosing regimen in a given renal category for patients with P. aeruginosa infections with ceftolozane/tazobactam MICs 8 mg/L cannot be endorsed without further clinical investigation.
A key discovery of this analysis is that extended infusions of 4-5 h conferred a higher PTA than continuous and shorter infusion rates in simulations of the augmented renal clearance state. While continuous infusions of b-lactams are often perceived to be better than extended infusions the reality is that continuous infusion either meets or does not meet the MIC exposure threshold creating an 'all or nothing' PTA result (0% or 100%). Since it is only required to be above the MIC for a fraction of the dosing interval to maximize the PK/PD profile of ceftolozane/tazobactam, the higher initial concentrations associated with extended infusion versus continuous infusions confer a more favourable PTA profile for infections with higher MICs. 9, 10, 15 The conclusions of this investigation are limited by its design, as this is a simulation-based investigation. Alternate definitions of augmented renal clearance exist in the literature based on the glomerular filtration rate scaled to body surface area. We relied on CL CR distributions because the population PK model was based on this parameter and not scaled to body surface area. Other groups have recently used a higher definition of 150-200 mL/min for augmented renal clearance when simulating standard ceftolozane/tazobactam dosing. 16 Although our simulations may overestimate the PTA in this subpopulation, the difference is marginal, as ceftolozane/tazobactam clearance scales as a power-function of CL CR . As a counter-point, we may have underestimated the PTA in critically patients with low serum protein concentration by using a fixed protein-binding estimate. We are also unable to estimate the safety of these alternate regimens given that specific exposure-safety breakpoints have not been defined for ceftolozane/tazobactam. In addition, the information gained from these data may be limited to PK/PD in the plasma compartment as tissue PK was not specifically modelled in this investigation. Finally, 40% fT .MIC is a well-recognized PK/PD target for b-lactams that may be too conservative 8, 16 or not conservative enough 13, 17 for ceftolozane/ tazobactam.
In conclusion, treatment of patients with MDR-PA infections often requires clinicians to use alternative dosing schemes for currently available agents to optimize their PK/PD profile. 10, 15 This investigation identified PK/PD optimized ceftolozane/tazobactam dosing schemes for the treatment of P. aeruginosa infections with ceftolozane/tazobactam MIC values between 4 and 32 mg/L among patients with varying degrees of estimated renal function. These analyses support the design of a targeted clinical trial of ceftolozane/tazobactam to validate the potential role of extended infusion regimens.
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